Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SAB Biotherapeutics (SABSW)

SAB Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SABSW
DateTimeSourceHeadlineSymbolCompany
20/05/202422:45GlobeNewswire Inc.SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesNASDAQ:SABSWSAB Biotherapeutics Inc
20/05/202421:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SABSWSAB Biotherapeutics Inc
06/05/202412:15GlobeNewswire Inc.SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
16/04/202412:15GlobeNewswire Inc.SAB Biotherapeutics Provides SAB-142 Trial UpdateNASDAQ:SABSWSAB Biotherapeutics Inc
08/04/202412:15GlobeNewswire Inc.SAB Biotherapeutics to Present at INNODIA Annual MeetingNASDAQ:SABSWSAB Biotherapeutics Inc
04/04/202412:15GlobeNewswire Inc.SAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
29/03/202411:15GlobeNewswire Inc.SAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
25/03/202414:15GlobeNewswire Inc.SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentNASDAQ:SABSWSAB Biotherapeutics Inc
23/02/202413:00GlobeNewswire Inc.SAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
08/02/202413:00GlobeNewswire Inc.SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
02/02/202412:30GlobeNewswire Inc.SAB Biotherapeutics Announces Executive Leadership ChangeNASDAQ:SABSWSAB Biotherapeutics Inc
23/01/202422:58GlobeNewswire Inc.SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:SABSWSAB Biotherapeutics Inc
02/01/202421:30GlobeNewswire Inc.SAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitNASDAQ:SABSWSAB Biotherapeutics Inc
29/11/202312:30GlobeNewswire Inc.SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
20/11/202312:30GlobeNewswire Inc.SAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
14/11/202312:30GlobeNewswire Inc.SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
14/11/202312:15GlobeNewswire Inc.SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesNASDAQ:SABSWSAB Biotherapeutics Inc
09/11/202312:30GlobeNewswire Inc.SAB Biotherapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
24/10/202312:30GlobeNewswire Inc.SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial OfficerNASDAQ:SABSWSAB Biotherapeutics Inc
19/10/202312:30GlobeNewswire Inc.SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
05/10/202312:30GlobeNewswire Inc.SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
02/10/202312:30GlobeNewswire Inc.SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
21/08/202313:30GlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q2 2023 Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
21/06/202313:30GlobeNewswire Inc.SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023NASDAQ:SABSWSAB Biotherapeutics Inc
30/05/202313:30GlobeNewswire Inc.SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International ConventionNASDAQ:SABSWSAB Biotherapeutics Inc
19/05/202313:30GlobeNewswire Inc.SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy InnovationsNASDAQ:SABSWSAB Biotherapeutics Inc
16/05/202313:30GlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
12/05/202313:30GlobeNewswire Inc.SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal AntibodiesNASDAQ:SABSWSAB Biotherapeutics Inc
09/05/202313:30GlobeNewswire Inc.SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ PlatformNASDAQ:SABSWSAB Biotherapeutics Inc
04/05/202313:30GlobeNewswire Inc.SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SABSW